References
- Gupta P, Bansal S, Gupta A, et al. Prevalence of arrhythmia in COVID-19 patients with mild/moderate and severe illness: a prospective cohort study. Expert Rev Cardiovasc Ther. 2023 Jun;21(6):453–461. doi: 10.1080/14779072.2023.2216456
- Mountantonakis SE, Saleh M, Fishbein J, et al. Northwell COVID-19 research consortium. Atrial fibrillation is an independent predictor for in-hospital mortality in patients admitted with SARS-CoV-2 infection. Heart Rhythm. 2021 Apr;18(4):501–507. doi: 10.1016/j.hrthm.2021.01.018
- Rosenblatt AG, Ayers CR, Rao A, et al. New-onset atrial fibrillation in patients hospitalized with COVID-19: results from the American Heart association COVID-19 cardiovascular registry. Circ Arrhythm Electrophysiol. 2022 May;15(5):e010666. doi: 10.1161/CIRCEP.121.010666
- Gawałko M, Kapłon-Cieślicka A, Hohl M, et al. COVID-19 associated atrial fibrillation: incidence, putative mechanisms and potential clinical implications. Int J Cardiol Heart Vasc. 2020 Oct;30:100631.
- Abani O, Abbas A, Abbas F, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 May 1;397(10285):1637–1645. doi: 10.1016/S0140-6736(21)00676-0
- WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group, Shankar-Hari M, Vale CL, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326(6):499–518. doi: 10.1001/jama.2021.11330
- Menchaca K, Ostos C, Draguljevic N, et al. protective influence of tocilizumab in Covid-19 patients with cardiac arrhythmias. J Am Coll Cardiol. 2023 Mar 7;81(8):79. doi: 10.1016/S0735-1097(23)00523-5
- Patel A, Jipescu D, Liu L, et al. Effect of tocilizumab on new onset atrial fibrillation and mortality in COVID-19 Patients: an umbrella review. J Am Coll Cardiol. 2022 Mar 8;79(9):2090. doi: 10.1016/S0735-1097(22)03081-9
- Zhang S, Li L, Shen A, Chen Y, et al. Rational use of Tocilizumab in the treatment of novel coronavirus pneumonia. Clin Drug Investig. 2020 Jun;40(6):511–518. doi: 10.1007/s40261-020-00917-3
- Rahman AK, Sahu N, Stoltzfus J, et al. Effects of Amiodarone on COVID-19 pneumonia outcomes. B40. Potpourri in ILD: spanning the spectrum from rare to common lung diseases. American Thoracic Society; 2023 May. p. pp. A3278–A3278. doi: 10.1164/ajrccm-conference.2023.207.1_MeetingAbstracts.A3278
- Lim S, Bae JH, Kwon HS, et al. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021 Jan;17(1):11–30. doi: 10.1038/s41574-020-00435-4
- Bosch NA, Cimini J, Walkey AJ. Atrial fibrillation in the ICU. Chest. 2018 Dec;154(6):1424–1434. doi: 10.1016/j.chest.2018.03.040
- Walkey AJ, Greiner MA, Heckbert SR, et al. Atrial fibrillation among medicare beneficiaries hospitalized with sepsis: incidence and risk factors. Am Heart J. 2013 Jun;165(6):949–955.e3. doi: 10.1016/j.ahj.2013.03.020
- Klein Klouwenberg PM, Frencken JF, Kuipers S, et al. MARS consortium *. Incidence, predictors, and outcomes of new-onset atrial fibrillation in critically ill patients with sepsis. A cohort study. Am J Respir Crit Care Med. 2017 Jan 15;195(2):205–211. doi: 10.1164/rccm.201603-0618OC